Metabolic and Morphologic Complications of HIV and HAART


•	Randomized, double-blind, placebo-controlled trial
•	178 HIV-infected patients with:
	-	Unintentional weight loss of >10% or
	-	A weight < 90% of lower limit of ideal body weight (BW)
•	Dose: 0.1 mg/kg BW/day (average 6 mg/day)
•	12-week duration

Schambelan M et al. Ann Intern Med. 1996;125:873-82.

• Treatment with growth hormone has been evaluated in a randomized, double-blind, placebo-controlled, multicenter trial.1

• The study enrolled 178 patients with HIV infection who had documented unintentional weight loss of at least 10%, or who had a weight less than 90% of the lower limit of ideal body weight.

• Participants received either recombinant human growth hormone or placebo. Dosing was 0.1 mg/kg of body weight per day, with an average of 6 mg/day.

• The study length was 12 weeks. Various outcome assessments were conducted at baseline, 6- and 12-week periods, including weight and body composition measurements.

Reference:

1. Schambelan M, Mulligan K, Grunfeld C, Daar ES et al. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim study group. Ann Intern Med. 1996;125:873-82.